IRF1 Inhibits Therapy-Induced Senescence of Glioblastoma Cells Through OAS2
Cells · 24.06.2026 · 15 (13) · 1149
DOI: 10.3390/cells15131149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 24.06.2026. Verfasst von Genli Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China. Hauptthemen laut MEDLINE: Interferon Regulatory Factor-1, Glioblastoma, Cellular Senescence, 2',5'-Oligoadenylate Synthetase. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wenzhou Medical University.
Abstract (Originalsprache)
Glioblastoma (GBM), a highly aggressive brain tumor, is characterized by poor treatment outcomes and a strong tendency to recur after therapy. Therapy-induced senescence (TIS) of GBM cells has emerged as a key driver of GBM progression and relapse. Temozolomide (TMZ), which serves as the standard chemotherapeutic agent for GBM, is known to induce senescence; however, the molecular mechanisms underlying this process remain largely unknown. In this work, we found that interferon regulatory factor-1 (IRF1) was downregulated in TMZ-induced senescent GBM cells. Functionally, knockdown of IRF1 increased the activity of senescence-associated β-galactosidase (SA-β-gal), reduced protein expression of Lamin B1, inhibited cell division, and enhanced senescence-associated secretory phenotype (SASP) of GBM cells, indicating that downregulation of IRF1 promotes senescence of GBM cells. Conversely, overexpression of IRF1 partially reversed TMZ-induced senescence. Further exploration revealed that downregulation of IRF1 reduced the expression of 2′,5′-oligoadenylate synthetase 2 (OAS2), and overexpression of IRF1 increased the expression of OAS2. OAS2 was also downregulated in TMZ-induced senescent GBM cells, and knockdown of OAS2 induced senescence of GBM cells as well. Taken together, our study reveals that IRF1 inhibits TMZ-induced senescence of GBM cells through OAS2, highlighting a novel regulatory axis that may offer potential therapeutic targets for improving GBM treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
ORCID-Profile: Xingxing Xu
Förderung
- Wenzhou Medical University
Zitieren
APA
Ma, G., Huang, W., Yan, H., Shen, B., Zhu, S., & Xu, X. (2026). IRF1 Inhibits Therapy-Induced Senescence of Glioblastoma Cells Through OAS2. Cells, 15(13), 1149. https://doi.org/10.3390/cells15131149
Vancouver
Ma G, Huang W, Yan H, Shen B, Zhu S, Xu X. IRF1 Inhibits Therapy-Induced Senescence of Glioblastoma Cells Through OAS2. Cells. 2026;15(13):1149. doi:10.3390/cells15131149
BibTeX
@article{Ma2026,
author = {Ma, Genli and Huang, Weiwei and Yan, Hangcong and Shen, Bin and Zhu, Shanli and Xu, Xingxing},
title = {IRF1 Inhibits Therapy-Induced Senescence of Glioblastoma Cells Through OAS2},
journal = {Cells},
year = {2026},
volume = {15},
number = {13},
pages = {1149},
doi = {10.3390/cells15131149}
}
EUVIMED